Methotrexate

Most Effective Atopic Dermatitis Treatments May Also Be Most Harmful

Retrieved on: 
Wednesday, February 21, 2024

"Atopic dermatitis is the most common inflammatory skin condition with an increasing number of available systemic interventions.

Key Points: 
  • "Atopic dermatitis is the most common inflammatory skin condition with an increasing number of available systemic interventions.
  • Competing treatment options exist for atopic dermatitis, but uncertainty regarding their comparative effectiveness still remains, the study showed.
  • Researchers examined the benefits and harms of all systemic and phototherapy treatments for atopic dermatitis in this network meta-analysis.
  • In randomized, controlled trials addressing systemic and phototherapy treatments for atopic dermatitis from MEDLINE, EMBASE, CENTRAL, Web of Science and GREAT, researchers performed Bayesian random-effects network meta-analyses on atopic dermatitis severity, itch severity, sleep disturbance, quality of life, exacerbations and adverse events.

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hukyndra, adalimumab, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Erelzi, etanercept, Date of authorisation: 23/06/2017, Revision: 14, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Erelzi, etanercept, Date of authorisation: 23/06/2017, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Erelzi, etanercept, Date of authorisation: 23/06/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Benepali, etanercept, Date of authorisation: 13/01/2016, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised